Lab Sciences
Top stories summarized by our editors
8/6/2018

The FDA has granted Siemens Healthineers clearance to market its Atellica IM BRAHMS PCT Assay for sepsis evaluation, mortality risk assignment and antibiotic therapy decision-making in intensive care units and emergency departments.

More Summaries:
FDA, Siemens, Siemens Healthineers
8/6/2018

University of Texas at Austin researchers found that the Cas12a enzyme used with CRISPR technology had increased precision compared with the Cas9 enzyme and strongly discriminated against mismatches in most of the DNA target sequence despite its functionally irreversible binding, which suggests that Cas12a's bonds during R-loop formation are reversible. However, the findings in the journal Molecular Cell showed that Cas12a was blind to certain RNA and genomic target mispairings, said researcher Ilya Finkelstein.

More Summaries:
CRISPR technology, Cas12a
8/6/2018

The health ministry of the Democratic Republic of Congo said 13 cases of Ebola virus infection have been confirmed, including three deaths. The ministry is investigating an additional 33 possible cases and is following over 875 people who may have had contact with people with the illness.

More Summaries:
Ebola
8/3/2018

Epizyme ended its development of tazemetostat as monotherapy and in combination with prednisolone in patients with diffuse large B-cell lymphoma because of the drug's lack of efficacy. The FDA in April put a partial clinical hold on the drug after a pediatric patient developed secondary lymphoma.

Full Story:
BioCentury
8/3/2018

Bristol-Myers Squibb received approval from the European Commission for its Opdivo, or nivolumab, as an adjuvant treatment for adult patients with BRAF mutant or wild-type melanoma involving the lymph nodes or metastatic disease after complete resection. An ongoing late-stage trial showed that the 18-month recurrence-free survival rate of patients was 66.4% for Opdivo compared to 52.7% for Yervoy.

Full Story:
PharmaBiz (India)
8/3/2018

The FDA has granted Hologic clearance to market its group B Streptococcus assay for use with its Panther Fusion module. The assay demonstrated 100% sensitivity in comparisons with culture-based tests, and sample storage requirements are less stringent.

More Summaries:
FDA, Hologic, Hologic
8/3/2018

Certain protein networks in the blood have been linked to conditions common in aging, according to a study published in Science. Researchers tested blood samples from more than 5,000 Icelanders over 66 and found 27 unique protein networks, with many showing patterns of expression that are associated with age-related conditions.

Full Story:
The Scientist online
8/3/2018

WHO emergency response chief Dr. Peter Salama said new cases of Ebola virus infection in the Democratic Republic of Congo pose a potential risk to the region due to their proximity to Uganda. Congo health officials said the cases involved the Zaire strain of the virus.

Full Story:
Reuters
8/3/2018

An analysis in JAMA Surgery of data for 750,937 patients found a 0.8% rate of postoperative venous thromboembolism, and the risk increased with each red blood cell transfusion patients received around the time of surgery. "We need to follow rigorous perioperative patient blood management practices. There is a need to correct preoperative anemia using nontransfusion alternatives whenever possible," said Dr. Aaron Tobian, a researcher in the study.

8/2/2018

Some hospitals in Ireland are using type O Rh-negative blood for transfusions by default rather than identifying the blood types of patients before transfusions are needed, the Irish Blood Transfusion Service said. The service has asked national health officials to discuss the issue with hospitals with the highest rates of using type O Rh-negative blood.